Skip to main content
. 2017 Sep 22;7:15–19. doi: 10.1016/j.omtm.2017.08.005

Figure 1.

Figure 1

Expedited and Exceptional Authorization Schemes in the EU

1The amount of therapeutic data available at the time of application submission is decreasing from the left to the right side of the scheme.

2PRIME-designated products are eligible to accelerated assessment.